Cart

Your cart is empty
On-Demand Webinar

Preventing Cisplatin-Induced Ototoxicity in Pediatrics: What You Need to Know to Improve Patient Outcomes

Overview 

Cisplatin is a commonly used chemotherapeutic agent for the treatment of certain childhood cancers, including germ cell tumors, hepatoblastoma, medulloblastoma, neuroblastoma, and osteosarcoma. However, as a known ototoxic agent, patients can risk permanent, bilateral hearing loss due to cisplatin use, with pediatric patients, especially younger children, at an increased risk for severe ototoxic effects. Hearing loss in this patient population can lead to delays in speech and language development and can also have a detrimental psychosocial and quality-of-life impact on pediatric, adolescent, and young adult patients receiving cisplatin therapy. 

This educational program will discuss the incidence and mechanism of cisplatin-induced ototoxicity. Expert faculty will share safety and efficacy data of sodium thiosulfate injection in the prevention of cisplatin-induced ototoxicity. The safety implications of select inactive ingredients in pharmaceutical products in the pediatric population will also be addressed. 

Objectives

  1. Understand the incidence and mechanism of cisplatin-induced ototoxicity in children.
  2. Discuss the mechanism of action and safety and efficacy data of sodium thiosulfate in the prevention of cisplatin-induced ototoxicity.
  3. Describe the safety impact of select inactive ingredients in pharmaceutical products in pediatric patients.

View Recording

Additional Resources

Speakers

Rita K. Jew, PharmD, MBA, BCPPS, FASHP
President, ISMP

 

 

Noah C. Federman, MD
Nancy and Jonathan Glaser Family Endowed Chair for Pediatric Sarcomas
Health Sciences Professor, Pediatrics and Orthopaedic Surgery 
Medical Director, CTSI Clinical and Translational Research Center
Director, UCLA CIRM Alpha Stem Cell Clinic
Director, UCLA Pediatric Bone and Soft Tissue Sarcoma Program,
UCLA Health; Jonsson Comprehensive Cancer Center; Clinical and Translational Science Institute; Mattel Children's Hospital and David Geffen School of Medicine

Sponsorship

This educational program is sponsored by Fennec Pharmaceuticals.